## **Cognition in MS**




**Cognitive symptoms** can occur early in MS and present in up to


Cognitive impairment can arise early<sup>1,3</sup>

**70%** of patients<sup>1</sup>

**92%** (n/N=12/13) of studies in a systematic review found that lower scores on cognitive assessments were significantly related to unemployment or reduced hours of work<sup>2</sup>

Early cognitive impairment may be associated with future disability<sup>4</sup>








In a multicenter trial of 29 patients with RIS and 26 patients with RRMS, 27.6% of patients with RIS had cognitive impairment<sup>d</sup> (similar to patients with RRMS), whereas lesion load and brain atrophy per MRI were comparable<sup>5</sup>



The SDMT is a reliable and valid measure of cognitive processing speed, a core cognitive ability that can be impacted in MS<sup>6</sup>





A **4-point change** (10% change) is widely accepted as a **clinically meaningful** change in cognitive function at a group level (eg, in clinical trials)<sup>7,e</sup>



An **8-point change** may be a valid threshold for **detecting cognitive changes** in an individual patient<sup>7</sup>



Declining SDMT scores were indicative of structural and functional changes in the brain and were associated with difficulty in day-to-day living acitivities<sup>8,9,f</sup>

<sup>a</sup>Retrospective 8-year longitudinal study in patients with RRMS. <sup>b</sup>Defined as a sustained increase in the EDSS of at least 1 point when EDSS was 5.5 or less (a sustained increase in EDSS of 0.5 point when EDSS was more than 5.5) independently from relapses and confirmed at least 12 months later<sup>4</sup>; <sup>c</sup>Single-center study of patients recruited into prospective cohort for clinical and MRI evaluation. <sup>d</sup>As assessed with the Rao Brief Repeatable Battery, which incorporates tests of verbal memory, visual memory, attention, concentration, and information processing speed <sup>e</sup>The 4-point change refers to the minimum overall mean change in a group associated with a clinically relevant anchor such as employment<sup>7</sup>; <sup>f</sup>Defined as annual days of sickness absence or disability pension<sup>9</sup>.

EDSS, Expanded Disability Status Scale; MRI, magnetic resonance imaging; MS, multiple sclerosis; RIS, radiologically isolated syndrome; RRMS, relapsing-remitting MS; SDMT, Symbol Digit Modalities Test

1. Alosaimi FD, et al. *Behav Neurol*. 2017;2017:6847070; 2. Clemens L, Langdon D. *Mult Scler Relat Disord*. 2018;26:183-91; 3. Oh J, et al. *Mult Scler*. 2021;27:2199-208; 4. Pitteri M, et al. *Mult Scler*. 2017;23:848-54; 5. Amato MP, et al. *Neurology*. 2012;78:309-14; 6. Langdon DW, et al. *Mult Scler*. 2012;18:891-8; 7. Weinstock Z, et al. *Mult Scler*. 2022;28:1101-11; 8. Benedict RHB, et al. *Lancet Neurol*. 2020;19:860-71; 9. Kavaliunas A, et al. *Mult Scler J Exp Transl Clin*. 2019;5:2055217318822134



©2025 Merck KGaA, Darmstadt, Germany, or its affiliates. All rights reserved. EMD Serono is the healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada | US-NONNI-02114 | January 2025